# Vir Biotechnology (VIR)

Vir Biotechnology, Inc. is a biopharmaceutical company that researches and develops treatments and therapies for infectious diseases, focusing on addressing emerging and pandemic threats.

### Just the Numbers

Total revenues for Q1 2024 were $56.4 million, compared to $63 million for the same period in 2023.

Cost of revenue for Q1 2024 was nominal compared to $1.9 million for Q1 2023.

R&D expenses for Q1 2024 were $100.1 million, a decrease from $157.6 million in Q1 2023.

SG&A expenses for Q1 2024 were $36.3 million, down from $46.8 million in Q1 2023.

Cash, cash equivalents, and investments at the end of Q1 2024 were $1.51 billion, down from $1.63 billion at the end of 2023.

### Beyond the Numbers

Clinical Development Programs: phase two SOLSTICE trial for chronic hepatitis delta, phase two March trial for chronic hepatitis B, and phase one trial for HIV T cell vaccine candidate.

Vir is advancing well in its clinical programs, reducing operating expenses through cost-saving measures and decreased spending on clinical trials. With a cash reserve of $1.5 billion, the company boasts a runway extending beyond 2.5 years. There are several important catalysts to watch out for through the rest of 2024:
